We should know about Novartis deal with ARDS in next couple weeks, if it goes through, Mesoblast will receive US$50m. SI mentioned CHF will get a major partner, if it goes through, MSB should receive at least US$100M for upfront payment. Do we know how much will be Grünenthal's payment for LBP? With those payments this year, MSB should have no concern for cash flow for next couple years, right? Or will we pay off some debt first? Either way, I think the risk for investing in MSB is pretty low, if we are aiming long term. As long as the plane doesn't crash, (which is unlikely, I do think SI is very good on fund raising) in next a few years, it will become rocket to Moon IMO.
We should know about Novartis deal with ARDS in next couple...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.060(5.83%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.10 | $1.03 | $4.925M | 4.571M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7260 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 67541 | 7 |
View Market Depth
| Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |